Originally published In Press as doi:10.1074/jbc.M207418200 on August 27, 2002
J. Biol. Chem., Vol. 277, Issue 44, 42386-42393, November 1, 2002
Transcriptional Activation of Interleukin-8 by
-Catenin-Tcf4*
Laurence
Lévy
,
Christine
Neuveut
,
Claire-Angélique
Renard
,
Pierre
Charneau§,
Sophie
Branchereau¶,
Frédéric
Gauthier¶,
Jeanne Tran
Van Nhieu
,
Daniel
Cherqui**,
Anne-France
Petit-Bertron
,
Danièle
Mathieu§§, and
Marie Annick
Buendia
¶¶
From the
Unité de Recombinaison et Expression
Génétique (Inserm U163), § Groupe de Virologie
Moléculaire et Vectorologie, and

Unité Cytokines et Inflammation,
Département de Médecine Moléculaire, Institut
Pasteur, 28 rue du Dr. Roux, 75015 Paris, ¶ Service de Chirurgie
Pédiatrique, Hôpital de Bicêtre, 94270 Le
Kremlin-Bicêtre,
Département de Pathologie and
** Service de Chirurgie Digestive, Hôpital Henri
Mondor, AP-HP and University Paris 12, 94010 Créteil, and
§§ Institut de Génétique
Moléculaire, UMR 5535, IFR 24, 1919 Route de Mende, 34293 Montpellier, France
Received for publication, July 24, 2002, and in revised form, August 23, 2002
 |
ABSTRACT |
Nuclear translocation of
-catenin and
its association with Tcf/Lef factors are key steps in transduction of
the Wnt signal, which is aberrantly activated in a variety of human
cancers. In a search for new
-catenin-Tcf target genes, we analyzed
-catenin-induced alterations of gene expression in primary human
hepatocytes, after transduction of either dominant stable
-catenin
or its truncated, transactivation-deficient counterpart by means of a
lentiviral vector. cDNA microarray analysis revealed a limited set
of up-regulated genes, including known Wnt targets such as matrilysin
and keratin-1. In this screen, we identified the CXC chemokine
interleukin 8 (IL-8) as a direct target of
-catenin-Tcf4. IL-8 is
constitutively expressed in various cancers, and it has been implicated
in tumor progression through its mitogenic, motogenic, and angiogenic
activities. The IL-8 promoter contains a unique consensus Tcf/Lef site
that is critical for IL-8 activation by
-catenin. We show here that the p300 coactivator was required for efficient transactivation of
-catenin on this promoter. Ectopic expression of
-catenin in
hepatoma cells promoted IL-8 secretion, which stimulated endothelial cell migration. These data define IL-8 as a Wnt target and suggest that
IL-8 induction by
-catenin might be implicated in developmental and
tumorigenic processes.
 |
INTRODUCTION |
The canonical Wnt/Wingless signaling pathway plays a pivotal role
in regulating growth and cell fate in early and late stages of
development (1, 2). These effects are achieved through the
stabilization of
-catenin and its translocation to the nucleus as a
coactivator for high mobility group-box proteins of the Tcf/Lef family (3, 4). In the absence of Wnt, a multiprotein complex including
the protein kinase GSK3
, adenomatous polyposis coli, and Axin
induces phosphorylation of
-catenin at N-terminal serine and
threonine residues, and phosphorylated
-catenin is directed toward
proteasome-mediated degradation (5, 6). Activation of Wnt
abrogates the degradation pathway, leading to elevated levels of
transcriptionally active
-catenin (7). Nuclear accumulation of
-catenin induces a transcriptional switch, in which Tcf-bound repressors (CtBP, TLE/Groucho, HDAC) are displaced by
-catenin and
its associated coactivators cAMP-response element-binding protein-binding protein/p300, Brg-1, TIP49/Pontin-52, and Bcl9-pygopus (8-12). The selective activation of distinct Wnt target genes in
proper context is strictly controlled by the interplay of positive and
negative regulatory signals on Wnt-responsive promoters (13, 14).
Aberrant activation of Wnt signaling is also implicated as a major step
in the development of various forms of human cancer (15). De-regulation
of
-catenin in cancer results mainly from genetic defects in the
N-terminal region of the
-catenin gene itself or in adenomatous
polyposis coli or Axin genes. The role of
-catenin is predominant at
early steps of colon carcinogenesis, in which truncating mutations of
adenomatous polyposis coli leading to elevated levels of
-catenin
account for about 80% of cases, whereas stable dominant
-catenin
mutants are present in one-half of the remaining cases (16). Activation
of Wnt signaling in hepatocellular carcinoma is mainly associated with
missense mutations of the
-catenin gene in about 20% of cases and
loss-of-function mutations of the Axin-1 gene in another 8% (17-19).
Liver-targeted expression of
-catenin transgenes induces
hepatomegaly in mice, but at difference with intestinal polyposis or
mammary cancer, stabilization of
-catenin appears to be insufficient
to cause short term liver cell transformation (20, 21).
A number of downstream target genes of Wnt signaling have been
identified in colorectal cancer. These genes play important roles in
neoplastic transformation, by affecting growth control and cell cycling
(c-Myc, cyclin D1, c-Jun, fra-1, gastrin, WISP-1, ITF-2), cell
survival (Id2, MDR1, COX2), or invasion and tumor dissemination
(matrilysin, laminin
2, VEGF) (22-31). However, although most
candidate
-catenin target genes were found to be up-regulated in
colon cancer (32), their implication in other tumor types has rarely
been investigated and remains to be determined. To better understand
the role of activated
-catenin in liver tumorigenesis, we sought to
identify genes that are deregulated by overexpression of a dominant
stable
-catenin mutant in primary human hepatocytes. These genes
were identified by analysis of expression profiles on cDNA arrays,
in cells infected with a lentiviral vector that allows expression of
transduced genes with high efficiency in nondividing cells (33). The
set of differentially expressed genes included previously described
targets of
-catenin, as well as known genes not previously linked to
the Wnt pathway. The current study demonstrates that the CXC chemokine
interleukin-8 (IL-8)1 is a
novel transcriptional target of the
-catenin-Tcf complex. IL-8
activities on cell growth, motility, and angiogenesis strongly suggest
that this chemokine might represent an important downstream effector of
the Wnt pathway during developmental and oncogenic processes.
 |
MATERIALS AND METHODS |
Plasmid Constructions--
A dominant stable
-catenin
carrying a mutation at residue 41 (threonine
alanine; T41A
-cat)
was generated by site-directed mutagenesis of full-length, myc-tagged
-catenin cDNA (a gift of J. Hulsken) and cloned into pcDNA3
as described previously (34). A truncated, transactivation-deficient
mutant of
-catenin (
N
C
-cat) was constructed by
amplification of the arm repeat domain (residues 130-680) by PCR with
appropriate primers providing an initiation codon and a stop codon and
was cloned into pcDNA3. The reporter plasmids pTOP-FLASH and
pFOP-FLASH and expression vectors for Tcf4 and myc-tagged dominant
negative
NTcf4 (4) were kindly provided by H. Clevers. The
expression vector for p300 was a gift of Y. Nakatani. IL-8 promoter
fragments of different sizes were amplified from human genomic DNA with
appropriate sets of primers (available upon request). Mutations of the
consensus Tcf/Lef binding site that abolished Tcf binding
(AAGATCAAAG
AAGGCCAAAG) were introduced in
the forward primer of the
193 IL-8 promoter construct. PCR products
were cloned into the pCRII-TOPO vector (Invitrogen), and
KpnI-XhoI fragments were subcloned into the
promoterless luciferase vector pGL3-Basic (Promega). All constructs were verified by sequencing.
Primary Cultures of Human Hepatocytes and
Fibroblasts--
Hepatocytes were prepared from resected normal human
livers adjacent to hepatoblastoma or to intrahepatic metastases of
breast or colon cancer or from residual graft donor liver fragments. All experimental procedures were conducted in conformity with French
laws and regulations and with informed consent of the patients. Hepatocytes were isolated by two-step collagenase perfusion as described previously (35). Briefly, after perfusion with calcium-free HEPES buffer, pH 7.7, and liver tissue digestion with HEPES containing 1 mg/ml collagenase D (Sigma) and 5 mM CaCl2,
the cell suspension was filtered through a 70-µm mesh cell strainer
(BD Biosciences). Cell debris and nonparenchymal cells were
partly eliminated by centrifugation at 700 rpm for 1.5 min, and cell
viability was assessed by a trypan blue exclusion test. The
hepatocyte-enriched fraction was seeded in William's medium on
collagen I-coated plates at 7 × 104 cells per
cm2, in William's medium supplemented with 10 nM insulin, 100 mM triiodothyronine, and 1 mg/ml bovine serum albumin.
Retroviral Vectors and Infection--
All constructs were
generated using the lentiviral vector pTRIP
U3 (36). The
pTRIP-
-cat and the pTRIP-
N
C
-cat constructs were generated
by cloning the BamHI-SalI fragment containing
full-length T41A
-catenin cDNA and the
BglII-XhoI fragment containing the truncated
-catenin mutant
N
C
-cat downstream of the cytomegalovirus promoter in the BamHI-XhoI sites of pTRIP. The
pTRIP-Tcf4 and pTRIP-
NTcf4 constructs were generated by cloning
BglII-XhoI fragments of Tcf4 and
NTcf4
cDNAs in the BamHI-XhoI sites of pTRIP. To obtain pTRIP-TOP and pTRIP-FOP, a 3130-bp PvuII fragment was
excised from pTOP-FLASH and pFOP-FLASH and cloned into blunted
MluI-XhoI sites of the lentiviral vector.
Virions were produced by transient calcium phosphate cotransfection of
293T cells as described previously (33). At 48 h post-transfection, supernatants were treated with DNase and
ultracentrifuged, and viral stocks were frozen at
80 °C. The
concentration of virion particles was normalized by measuring the p24
capsid protein by ELISA (PerkinElmer Life Sciences). Cells were
incubated for 2 h with virions at a concentration of 800 ng of
viral p24/ml in one-tenth of the usual volume of William's medium.
Fresh medium was then added, and cell were further incubated for
48 h.
RNA Analysis and Hybridization of cDNA Arrays--
Total RNA
was extracted from primary cells and cell lines using the RNA-PLUS
extraction solution (Quantum Biotechnologies). For hybridization of
Atlas Plastic Human 8K microarrays (Clontech), 33P-labeled probes were generated by reverse transcription
of 20 µg of total RNA according to the manufacturer's instructions. After hybridization, filters were scanned at 50-µm resolution using a
Fuji BAS-5000 phosphorimager. Data were processed using Clontech AtlasImage 2.01 software. Intensities were
adjusted through a median normalization, and differential expression
was considered significant when signal ratio for the same spot was
2. For Northern blotting, 10 µg of total RNA was analyzed by
alkaline blot as described previously (37). For RT-PCR, up to 2 µg of
total RNA was reverse-transcribed using Superscript II RT RNase
H-Reverse Transcriptase (Invitrogen) and oligo(dT) primers.
Amplifications were carried out in PCR exponential phase (20-35
cycles) to allow comparison among cDNAs synthesized from identical
reactions. PCR products were analyzed in 1.5% agarose gels. The
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
amplified as control. Primer sequences are as follows: Keratin-F,
5'-gagtaccaggaggtgatgaactcc-3'; Keratin-R,
5'-AACACAGATCAAGAGCAG-3'; MMP7-F,
5'-GCAGCTATGCGACTCACCG-3'; MMP7-R,
5'-CTGCCTGAAGTTTCTATTTC-3'; IL-8-F,
5'-CATGACTTCCAAGCTGGCCG-3'; IL-8-R, 5'-TTTATGAATTCTCAGCCCTC-3';
GAPDH-F, 5'-ACCACAGTCCATGCCATCAC-3'; GAPDH-R,
5'-TCCACCACCCTGTTGCTGTA-3'.
Cell lines, Transfections, and Reporter Assays--
The human
kidney cell line 293, the hepatoma cell lines Huh7 and HepG2, and the
immortalized human hepatocytes LO2 (38) (a kind gift of P. Pineau),
were maintained in Dulbecco's modified Eagle's medium with 10% fetal
bovine serum. For reporter assays, semi-confluent cells in 6-well
plates were transiently transfected by calcium phosphate precipitation
with expression vectors for
-catenin, Tcf4,
NTcf4, or p300, and
0.1 µg of different pIL-8-LUC constructs. Luciferase activity was
determined 48 h later. All experiments were performed in duplicate
and repeated at least three times. A thymidine kinase-
-galactosidase
plasmid was cotransfected to normalize luciferase activity for
transfection efficiency. However, because p300 was found to activate
transcription of this reporter, it could not be used for normalization,
and results were confirmed by multiple independent assays. The total
amount of transfected DNA was kept constant by adding pcDNA3.
Western Blotting--
Cells were lysed in chilled lysis buffer
(50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1%
Nonidet P-40, 1 mM Na3VO4, 1 mM NaF) supplemented with protease inhibitors (Roche
Molecular Biochemicals). Whole cell extracts were resolved in 8-16%
Tris-HCl polyacrylamide gels (Novex) and transferred to Hybond-C extra
membranes (Amersham Biosciences). Western blots were probed with
a monoclonal anti-
-catenin antibody (Transduction Laboratories) or a
polyclonal anti-IL-8 antibody (BIOSOURCE),
followed by secondary antibodies. Immunoreactive proteins were
visualized using protocols and reagents of the Western CDP-star kit
(PerkinElmer Life Sciences).
Cytokine ELISA--
LO2 cells were plated at 104
cells/ml, infected with different lentivirus vectors as indicated, and
supernatants were collected at different times and frozen immediately.
IL-8 ELISA was performed on 1-ml aliquots as described previously (39),
using a monoclonal anti-human IL-8 antibody provided by J-C.
Mazié (Hybridolab, Institut Pasteur) and a rabbit polyclonal
anti-IL-8 antibody kindly provided by Dr. N. Vita (Sanofi Recherche,
Labège, France).
Endothelial Cell Culture and Migration Assays--
Human
umbilical vein endothelial cells (HUVECs) (Clonetics; BioWhittaker)
were propagated through passage 6 in MCDB131 medium (Invitrogen)
supplemented with 2 mM Glutamax (Invitrogen), 12% fetal
calf serum, 10 units/ml porcine heparin (Sigma), 10 ng/ml hu-EGF
(Peprotech Inc.), 35 µg/ml endothelial cell growth supplement (BD
Biosciences), and 1 µg/ml hydrocortisone (Sigma). Subconfluent HUVECs
were starved for 2-3 h in M199 medium containing 2% fetal calf serum
and 1 µM Calcein-AM (Molecular Probes) for cell labeling. Cells were trypsinized, pelleted, and resuspended in M199 medium containing 0.1% fatty acid-free bovine serum albumin (I. D. Bio, Limoges, France). Cells (5 × 104 per well) were
placed in the upper chambers of 8-µm cell culture inserts (Falcon HTS
Fluoroblock; BD Biosciences) coated with 50 µg/ml collagen I. The
lower wells contained conditioned medium from LO2 cells infected with
different pTRIP constructs as indicated. For control, we used either
M199 with 0.1% bovine serum albumin (background control) or MCDB 131 containing 8% fetal calf serum and 30% conditioned medium from
differentiating primary human erythroblasts (control chemoattractant
medium) (40). IL-8-neutralizing antibody or control goat IgG (1 µg/well) was included in lower wells 30 min before migration was
monitored. After incubation for 2 h at 37 °C, cells on the
upper side of the filters were washed off, and cells that had migrated
through the filters were fixed in formalin, stained with propidium
iodide (2 µg/ml in phosphate-buffered saline, overnight at 4 °C),
and counted under a fluorescent microscope. At least ten random fields
per well at 32× magnification were counted for each experiment.
 |
RESULTS |
Identification of Downstream Target Genes of
-Catenin in Primary
Human Hepatocytes--
To identify genes whose expression is regulated
by
-catenin-Tcf in the liver context, we analyzed differentially
expressed genes by microarray profiling in primary human hepatocytes
after
-catenin gene transfer. Human hepatocytes at 24 h
post-plating were infected with the lentiviral vector pTRIP
U3 (36)
or with a recombinant vector (pTRIP-
-cat) expressing the stable
dominant T41A
-catenin under control of the cytomegalovirus
promoter. The TRIP vector was chosen, because it allows high
transduction efficiency in differentiated, nondividing cells (33). Our
preliminary experiments with pTRIP-
-cat indicated that over 90% of
hepatocytes abundantly expressed
-catenin in the nucleus. Moreover,
co-infections with pTRIP-
-cat and vectors expressing the luciferase
reporter under control of consensus Tcf binding motifs (pTRIP-TOP) or
its mutated, unresponsive version (pTRIP-FOP) indicated that activation of Tcf-mediated transcription reached maximal values at 48 h (data not shown). This time was therefore selected in microarray experiments. To discriminate direct transcriptional targets of the
-catenin-Tcf complex among deregulated genes, we also infected hepatocytes with an
expression vector for truncated
-catenin retaining the central arm
repeat region and devoid of transactivation activity (pTRIP-
N
C
-cat). As shown in Fig.
1A, both full-length and
truncated
-catenin were highly expressed in infected
hepatocytes.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 1.
IL-8 is up-regulated by
-catenin-Tcf4 in hepatocytes and hepatoma cell
lines. A, primary human hepatocytes at 24 h
post-plating were infected with 800 ng/ml of either
pTRIP- N C -cat encoding the arm repeat domain of -catenin or
pTRIP- -cat, alone or along with pTRIP-Tcf4 or pTRIP- NTcf4. Total
RNA was extracted from each culture 48 h after infection, and 10 µg of RNA was analyzed by Northern blotting with -catenin and Tcf4
probes. An 18 S cDNA probe served as control for equal loading.
B, -catenin-driven up-regulation of the candidate target
gene IL-8 and the known Wnt-responsive genes MMP7 and keratin-1 was
confirmed by RT-PCR, using 2 µg of RNA from infected hepatocytes. The
transactivation-deficient N C -catenin had only a modest
effect, and the dominant negative Tcf4 strongly down-regulated IL-8 and
MMP7 expression. C, IL-8 expression was analyzed by RT-PCR
in the hepatoma cell lines Huh7 and LO2 infected or not with the empty
vector and with pTRIP- -cat. Expression of GAPDH served as control.
NI, not infected.
|
|
cDNA probes were generated from the RNA of primary human
hepatocytes infected with pTRIP-
-cat, pTRIP-
N
C
-cat, and
empty vector. These probes were used for differential hybridization with a cDNA array (Atlas 8K; Clontech)
containing 8,000 sequence-verified, known human genes. Around 1,200 genes were detectably expressed in cultured hepatocytes, including
liver markers such as hepatic arginase and hepatic lipase, consistent
with the observed persistence of hepatocyte-like morphology during
short term culture. We have compared the expression profiles between
hepatocytes infected with pTRIP-
-cat and the empty vector and
identified 200 genes that were differentially expressed by 2-fold or
higher, including 57 genes that were up-regulated. In a second step,
expression profiles were compared between cells expressing T41A
-catenin and those expressing the transactivation-deficient
N
C
-catenin. Forty-two of the 57 genes were still expressed
differentially, suggesting that their up-regulation was dependent upon
-catenin transactivation activity. Among these genes, we noted known
Wnt-responsive genes such as matrilysin (MMP7) and basic keratin-1
genes, as well as a member of the WISP family, the connective
tissue growth factor (Table I),
whereas cyclin D1 expression remained undetectable in all settings.
View this table:
[in this window]
[in a new window]
|
Table I
Selected genes differentially expressed in cDNA array screens
Expression profiles were compared between hepatocytes infected with
pTRIP- -cat or the empty vector and between hepatocytes infected with
pTRIP vectors expressing dominant stable -catenin or the truncated,
inactive N C -catenin. The ratios of signal intensities obtained
for four genes up-regulated by -catenin are shown. -Catenin data
are presented as control. Note that N C -catenin did not
hybridize with C-terminal -catenin cDNA sequences spotted on the
array.
|
|
Up-regulation of IL-8 by
-Catenin-Tcf4--
Search for
consensus Tcf binding sites in the promoters of candidate genes
revealed the presence of AAGATCAAAG sequences at position
186 to
177 in the IL-8 promoter. IL-8 mRNA was enhanced 4.6-fold by
-catenin in the first cDNA array screen and was still higher in
the second screen when cells expressing transcriptionally active
-catenin were compared with those expressing transcription-defective
-catenin (Table I). Differential expression of IL-8 in
-catenin-expressing cells was confirmed by semi-quantitative RT-PCR
analysis in two independent primary hepatocyte cultures, as also found
for MMP7 and keratin-1 genes (Fig. 1B). Furthermore, IL-8
mRNA levels were higher in hepatocytes expressing constitutively
active
-catenin than in those expressing
N
C
-catenin. To
assess whether IL-8 transcriptional activation was
Tcf4-dependent, we performed co-infections with
pTRIP-
-cat and vectors expressing either wild type Tcf4 (pTRIP-Tcf4)
or a dominant negative mutant devoid of
-catenin binding domain
(pTRIP-
NTcf4). Efficient expression of wild type and mutant Tcf4 in
hepatocytes was verified by Northern blotting (Fig. 1A). The
NTcf4 mutant strongly inhibited
-catenin-induced IL-8 expression
(Fig. 1B). Similar data were obtained in the well differentiated hepatic cell lines Huh7 and LO2, in which the
-catenin pathway is not activated constitutively (Fig.
1C).
Up-regulation of IL-8 was also evidenced, both at mRNA and protein
levels, in LO2 cells after treatment with LiCl 20 mM (Fig. 2). LiCl is an inhibitor of GSK3
that
induces strong accumulation of dephosphorylated
-catenin and
increased activity of the synthetic Tcf-dependent
luciferase reporter TOPFLASH (7). In our experiments, IL-8 mRNA was
induced at 24 h of LiCl treatment, when the levels of
-catenin
were increased markedly, whereas IL-8 protein was detectable at 48 h, strongly suggesting direct activation of IL-8 expression by
-catenin (Fig. 2). By contrast, we repeatedly failed to detect any
change in IL-8 mRNA levels after transduction of
-catenin into
primary human fibroblasts, although efficient expression of
-catenin
from the pTRIP vector in these cells was verified by Northern blotting
(data not shown). This suggests that
-catenin-driven induction of
IL-8 expression might be dependent on cellular context.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
LiCl induces IL-8 expression. LO2 cells
were incubated with 20 mM LiCl for different times as
indicated. Total lysates were prepared, and expression of -catenin
and IL-8 proteins was assessed by Western blot analysis using 30 µg
of cell lysate per lane (upper panel). Total RNA
was isolated from cells harvested at the same time points, and IL-8
mRNA was analyzed by RT-PCR using GAPDH as a control (lower
panel).
|
|
Transactivation of the IL-8 Promoter by the
-Catenin-Tcf4
Complex--
The presence of a consensus Tcf/Lef binding motif in the
IL-8 promoter (Fig. 3A)
prompted us to examine the effects of
-catenin and Tcf4 expression
on IL-8 promoter activity. Two hepatoma cell lines were used, Huh7, in
which normal
-catenin is localized to the cell membrane, and HepG2,
which exhibits nuclear accumulation of N-terminally deleted
-catenin
(17). A 1.4-kb IL-8 promoter-luciferase construct (1400-IL-8-LUC) was
transfected into Huh7 and HepG2 cells, along with different
-catenin
and Tcf4 expression vectors. In HepG2 cells, transfection of increasing
amounts of Tcf4 further stimulated the basal IL-8 promoter activity up
to 3-fold, whereas
NTcf4 reduced the basal activity up to 9-fold in
a dose-dependent manner (Fig. 3B). In Huh7
cells, the IL-8 promoter was activated 2-fold by cotransfection with
-catenin, and
NTcf4 inhibited
-catenin-driven transactivation
(Fig. 3C).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 3.
The IL-8 promoter is activated by
-catenin-Tcf4. A, schematic
representation of the IL-8 promoter and binding sites for multiple
nuclear factors. A putative Tcf/Lef binding element is localized at
position 186 bp from the transcription start site. B,
HepG2 cells containing a constitutively activated -catenin allele
were cotransfected with 0.1 µg of a reporter plasmid containing 1.4 kb of the IL-8 promoter (1400-IL-8-LUC) and 1-4 µg of Tcf4 or
NTcf4 expression vector and harvested 48 h after transfection.
Total amounts of plasmid DNA were kept constant by adding the empty
pcDNA3 vector. All experiments were performed in duplicate and
repeated at least three times. Means ± S.D. are presented.
C, Huh7 cells containing normal endogenous -catenin were
transiently transfected with 0.1 µg of 1400-IL-8-LUC, along with 1 µg of T41A -catenin and/or 3 µg of NTcf4 expression vector.
D, IL-8 promoter transactivation by the p300 coactivator.
Huh7 cells were transfected with the 1400-IL-8-LUC reporter (0.1 µg),
along with expression vectors for -catenin (0.5 µg) and/or p300 (3 µg).
|
|
Because interaction of the cAMP-response element-binding
protein-binding protein and p300 coactivators with
-catenin has been
shown to potentiate transcriptional activation of some Wnt-responsive genes (11), we next tested whether p300 cooperates with
-catenin in
IL-8 promoter activation. As shown in Fig. 3D, coexpression of p300 and
-catenin, along with the IL-8 promoter construct in Huh7
cells, resulted in an 8-fold increase in luciferase activity, whereas
p300 had little activity in the absence of
-catenin. Similar data
were obtained in 293 cells. Thus, p300 is required for robust
-catenin responsiveness of the IL-8 promoter.
To determine the functional significance of consensus Tcf/Lef binding
sequences at nucleotides
186 to
177, we first employed a series of
5' promoter deletion constructs (Fig.
4A). In Huh7 cells, a
2-3-fold induction in the IL-8 promoter activity by
-catenin was
conserved for the 500-, 230-, and 193-bp proximal promoter fragments,
but
-catenin had no effect on the
173 construct, in which the
putative site was deleted (Fig. 4B). Conversely, in HepG2
cells, similar basal activity was observed for the 1.4-kb to 193-bp
promoter fragments, whereas the
173 construct showed a 2-fold lower
activity (Fig. 4C). Furthermore, basal activity of the
1.4-kb to 193-bp promoter constructs was 8- to 10-fold down-regulated
by
NTcf4 in these cells, but the 173-bp fragment showed only a
2-fold decrease, which is consistent with positive regulation of the
IL-8 promoter by the
-catenin-Tcf complex. The functional
significance of the consensus Tcf/Lef binding motif was assessed
further by introducing point mutations in the context of the
193 IL-8
promoter (Fig. 5A). Mutation
of the Tcf/Lef binding motif abolished transactivation of this
construct by
-catenin in Huh7 cells (Fig. 5B). In HepG2
cells, basal activity of the mutated
193 construct was reduced by
3-fold, indicating that the
-catenin-Tcf4 complex contributes to a
significant extent to constitutive IL-8 expression in these cells.
Accordingly, the inhibitory effect of
NTcf4 on 193mut-IL8-LUC
activity was decreased strongly compared with the corresponding wild
type reporter (Fig. 5C). These data show that induction of
IL-8 by
-catenin is controlled at the transcription level and
depends on a single Tcf/Lef binding site.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Identification of
-catenin-responsive element by deletion analysis of
the IL-8 promoter. A, successive deletion constructs of
the 1.4-kb IL-8 promoter (500, 230, 193, and 173 bp) in the pGL3
luciferase reporter plasmid. B, these constructs were
transfected into Huh7 cells, along with a -catenin expression vector
or the empty vector as described in the legend for Fig. 3.
C, HepG2 cells were cotransfected with 0.1 µg of the
indicated IL-8 promoter constructs and 4 µg of NTcf4 expression
vector or empty pCDNA3 vector.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
The Tcf/Lef binding sequence at position
186 is crucial for activation of the IL-8 promoter by
-catenin-Tcf4. A, point mutations
known to abolish Tcf binding were introduced into the Tcf/Lef
recognition site in the context of the 193 IL-8 promoter.
B, Huh7 cells were transfected with wild type or mutated
193-IL8-LUC reporter, along with -catenin or empty vector as
indicated in the legend for Fig. 3. C, HepG2 cells were
cotransfected with wild type or mutant 193-IL8-LUC reporter and
dominant negative Tcf4 or the empty vector.
|
|
-Catenin Induces Secretion of IL-8 with Chemoattractant
Activity--
It has been shown that the IL-8 chemokine is involved in
angiogenesis (41). To assess the biological significance of IL-8 induction by
-catenin, we thought to determine whether
overexpression of
-catenin was associated with secretion of
functionally active IL-8. LO2 cells expressing low, barely detectable
levels of IL-8 were infected with pTRIP-
-cat, pTRIP-
NTcf4, or
empty vector. Cells were washed, fresh medium was added 2 h later,
and conditioned media were analyzed by ELISA at different times.
Significant secretion of IL-8 was seen at 48 h in
-catenin-expressing cells but not in cells infected with empty
vector or in the presence of dominant negative Tcf4 (Fig.
6). The level of IL-8 protein increased
further after 48 h because of persistent expression of
-catenin
transduced by the lentiviral vector (data not shown). It has been shown
that the IL-8 chemokine can induce migration of cells expressing the CXC chemokine receptors, notably endothelial cells (42). To determine
whether
-catenin-driven IL-8 release might exert chemoattractant effects on neighboring cells, migration analysis was
performed using HUVECs and chamber assembly. Migration of HUVECs
was stimulated by conditioned media from untreated HepG2 cells or from
LO2 cells infected with pTRIP-
-cat but not from LO2 cells infected
with the empty vector. Importantly, stimulation levels decreased to background when IL-8-neutralizing antibody was added prior to the
migration test (Fig. 7). These data show
that
-catenin-induced migration of endothelial cells is mediated by
IL-8.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
-Catenin induces secretion of
IL-8. LO2 cells were plated at 104 cells/ml in 12-well
plates and infected with TRIP- -cat alone or along with
TRIP- NTcf4. Noninfected cells and cells infected with the empty
vector served as controls. Fresh medium was added 2 h
post-infection, and supernatant was collected at different times as
indicated for ELISA tests of IL-8 production.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
-Catenin has chemoattractant
effect through the induction of IL-8. LO2 cells (2 × 105 cells per well in 6-well plates) were infected with
pTRIP- -cat or empty vector, supernatants were discarded 24 h
post-infection, and cells were incubated in fresh medium for 48 h.
Migration assays were performed using HUVECs and chambers of 8-µm
cell culture inserts in the presence of 48-h conditioned medium from
infected LO2 cells or from noninfected (NI) HepG2 cells.
Neutralizing antibody against IL-8 (1 µg/well) was added to determine
the functional contribution of IL-8 on cell migration. Nonspecific goat
antibody was used to control the specificity of the inhibition. At
least ten random fields per well were counted for each experiment. Data
were gathered from three independent assays.
|
|
 |
DISCUSSION |
In this study, we have identified the CXC chemokine IL-8 as a gene
up-regulated by
-catenin by using microarray technology and primary
human hepatocytes that expressed stabilized or transcription-defective
-catenin. We show that endogenous IL-8 mRNA is induced in
hepatocytes and hepatoma cell lines by ectopic overexpression of
dominant stable
-catenin, as well as by LiCl treatment, which
inactivates GSK3
and therefore stabilizes wild type
-catenin.
This regulation occurs at the transcription level, because the IL-8
promoter responded to
-catenin in Huh7 cells expressing low wild
type
-catenin and to Tcf4 in HepG2 cells expressing elevated mutant
-catenin whereas dominant negative Tcf4 inhibited these effects. Our
data demonstrate that a single consensus Tcf/Lef binding sequence
located 186 bp from the transcriptional start site is critical for
-catenin responsiveness, thus identifying IL-8 as a direct target of
-catenin-Tcf4. Although activation levels triggered by
-catenin
alone were weak, the p300 coactivator cooperated strongly with
-catenin to specifically activate the IL-8 promoter. Thus, in this
promoter context,
-catenin recruits p300 as a coactivator for
efficient transactivation, as reported previously for the
siamois promoter (11).
IL-8 is constitutively up-regulated in a variety of human cancers such
as melanoma and lung, gastric, prostate, and bladder cancers (43-46).
Interestingly, up-regulation of IL-8 has been linked recently to
-catenin activation based on microarray analysis of differentially
expressed genes between normal and neoplastic colon.2 In
hepatocellular carcinoma, overexpression of IL-8 has also been observed
in about half of the cases, and tumor cells were shown to represent the
major source of IL-8 production (47). Hepatocellular carcinomas develop
on a background of chronic hepatitis or cirrhosis, in which viral and
inflammatory factors trigger potent IL-8 induction (48). Moreover, the
IL-8 gene has been identified as a target of hepatocyte growth factor
and insulin-like growth factor-1 (49, 50), and activation of either of
these pathways also leads to nuclear activation of
-catenin (51, 52). Therefore, IL-8 expression levels in cancer cells might be
modulated by a complex interplay of signaling pathways.
The pleiotropic activities of IL-8 as a mitogenic, motogenic, and
angiogenic factor (53) imply that the chemokine might play important
roles in development and tumorigenesis. Although the role of IL-8 at
developmental stages remains to be documented, it has been shown that
IL-8 acts as an autocrine growth factor for a variety of cancer cell
lines. The IL-8 receptors CXCR1 and CXCR2 are expressed in hepatoma
cells (54), and antisense oligonucleotides or IL-8-neutralizing
antibodies can suppress growth of various cancer cells (46). We found
recently that exposure of hepatoma cells to IL-8 activates the
mitogen-activated protein kinase pathway and the phosphorylation of
extracellular signal-regulated kinase 1/2, which are important
mediators of growth signals from cell surface receptors to the
nucleus.3
A major role of IL-8 in tumor angiogenesis has been demonstrated by
functional studies showing its ability to induce endothelial cell
chemotaxis and neovascularization (41, 44). In this study, we show that
-catenin-expressing cells induce migration of human vascular
endothelial cells. IL-8-neutralizing antibodies abolished this effect,
indicating that this motogenic activity is mediated directly by IL-8 in
hepatoma cells.
-Catenin might influence angiogenesis by activating
a combination of several proangiogenic factors, such as vascular
endothelial growth factor, which was also identified recently as a
target of the Wnt/
-catenin pathways (30). Importantly, IL-8 is also
involved in tumor invasion and metastasis (46, 47). It has been
reported that IL-8 increases the expression of metalloproteinases MMP2
and MMP9 in human melanocytes (45). Matrilysin (MMP7), which we found
up-regulated by
-catenin in hepatocytes, and laminin
2 are other
Wnt target genes implicated in tumor invasiveness. In colon cancer,
overexpression of
-catenin and its target genes at invasive tumor
fronts has been correlated with increased risk of tumor recurrence and
poor outcome (55, 56). The present study, linking IL-8 to the Wnt
pathway, further emphasizes the role of tumor microenvironment in
cancer progression and provides new insight into
-catenin functions
in vasculogenesis and angiogenesis.
 |
ACKNOWLEDGEMENTS |
We thank Drs. H. Clevers, J. Hulsken, and Y. Nakatani for providing plasmids and Julien Pothlichet for help as a
graduate student. We are grateful to Pierre Tiollais for constant
interest in this work.
 |
FOOTNOTES |
*
This work was supported in part by the Association pour la
Recherche sur le Cancer (ARC) (to L. L.) and by Grant 5236 from the
ARC.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶¶
To whom correspondence should be addressed. Tel.:
33-145-68-88-66; Fax: 33-145-68-89-43; E-mail:
mbuendia@pasteur.fr.
Published, JBC Papers in Press, August 27, 2002, DOI 10.1074/jbc.M207418200
2
David Jones, personal communication.
3
L. Lévy, Unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
IL, interleukin;
RT, reverse transcriptase;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
ELISA, enzyme-linked immunosorbent assay;
HUVEC, human umbilical vein
endothelial cell;
LUC, luciferase.
 |
REFERENCES |
| 1.
|
Cadigan, K. M.,
and Nusse, R.
(1997)
Genes Dev.
11,
3286-3305[Free Full Text]
|
| 2.
|
Peifer, M.,
and Polakis, P.
(2000)
Science
287,
1606-1609[Abstract/Free Full Text]
|
| 3.
|
Behrens, J.,
von Kries, J. P.,
Kuhl, M.,
Bruhn, L.,
Wedlich, D.,
Grosschedl, R.,
and Birchmeier, W.
(1996)
Nature
382,
638-642[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Korinek, V.,
Barker, N.,
Morin, P. J.,
van Wichen, D.,
de Weger, R.,
Kinzler, K. W.,
Vogelstein, B.,
and Clevers, H.
(1997)
Science
275,
1784-1787[Abstract/Free Full Text]
|
| 5.
|
Rubinfeld, B.,
Albert, I.,
Porfiri, E.,
Fiol, C.,
Munemitsu, S.,
and Polakis, P.
(1996)
Science
272,
1023-1026[Abstract]
|
| 6.
|
Yost, C.,
Torres, M.,
Miller, J. R.,
Huang, E.,
Kimelman, D.,
and Moon, R. T.
(1996)
Genes Dev.
10,
1443-1454[Abstract/Free Full Text]
|
| 7.
|
Staal, F. J.,
van Noort, M.,
Strous, G. J.,
and Clevers, H. C.
(2002)
EMBO Rep.
3,
63-68[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Barker, N.,
Hurlstone, A.,
Musisi, H.,
Miles, A.,
Bienz, M.,
and Clevers, H.
(2001)
EMBO J.
20,
4935-4943[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Bauer, A.,
Chauvet, S.,
Huber, O.,
Usseglio, F.,
Rothbacher, U.,
Aragnol, D.,
Kemler, R.,
and Pradel, J.
(2000)
EMBO J.
19,
6121-6130[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Billin, A. N.,
Thirlwell, H.,
and Ayer, D. E.
(2000)
Mol. Cell. Biol.
20,
6882-6890[Abstract/Free Full Text]
|
| 11.
|
Hecht, A.,
Vleminckx, K.,
Stemmler, M. P.,
van Roy, F.,
and Kemler, R.
(2000)
EMBO J.
19,
1839-1850[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Kramps, T.,
Peter, O.,
Brunner, E.,
Nellen, D.,
Froesch, B.,
Chatterjee, S.,
Murone, M.,
Zullig, S.,
and Basler, K.
(2002)
Cell
109,
47-60[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Hecht, A.,
and Kemler, R.
(2000)
EMBO Rep.
1,
24-28[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Barolo, S.,
and Posakony, J. W.
(2002)
Genes Dev.
16,
1167-1181[Free Full Text]
|
| 15.
|
Polakis, P.
(2000)
Genes Dev.
14,
1837-1851[Free Full Text]
|
| 16.
|
Morin, P. J.
(1999)
Bioessays
21,
1021-1030[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
de La Coste, A.,
Romagnolo, B.,
Billuart, P.,
Renard, C. A.,
Buendia, M. A.,
Soubrane, O.,
Fabre, M.,
Chelly, J.,
Beldjord, C.,
Kahn, A.,
and Perret, C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8847-8851[Abstract/Free Full Text]
|
| 18.
|
Satoh, S.,
Daigo, Y.,
Furukawa, Y.,
Kato, T.,
Miwa, N.,
Nishiwaki, T.,
Kawasoe, T.,
Ishiguro, H.,
Fujita, M.,
Tokino, T.,
Sasaki, Y.,
Imaoka, S.,
Murata, M.,
Shimano, T.,
Yamaoka, Y.,
and Nakamura, Y.
(2000)
Nat. Genet.
24,
245-250[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Laurent-Puig, P.,
Legoix, P.,
Bluteau, O.,
Belghiti, J.,
Franco, D.,
Binot, F.,
Monges, G.,
Thomas, G.,
Bioulac-Sage, P.,
and Zucman-Rossi, J.
(2001)
Gastroenterology
120,
1763-1773[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Cadoret, A.,
Ovejero, C.,
Saadi-Kheddouci, S.,
Souil, E.,
Fabre, M.,
Romagnolo, B.,
Kahn, A.,
and Perret, C.
(2001)
Cancer Res.
61,
3245-3249[Abstract/Free Full Text]
|
| 21.
|
Harada, N.,
Miyoshi, H.,
Murai, N.,
Oshima, H.,
Tamai, Y.,
Oshima, M.,
and Taketo, M. M.
(2002)
Cancer Res.
62,
1971-1977[Abstract/Free Full Text]
|
| 22.
|
He, T. C.,
Sparks, A. B.,
Rago, C.,
Hermeking, H.,
Zawel, L.,
da Costa, L. T.,
Morin, P. J.,
Vogelstein, B.,
and Kinzler, K. W.
(1998)
Science
281,
1509-1512[Abstract/Free Full Text]
|
| 23.
|
Pennica, D.,
Swanson, T. A.,
Welsh, J. W.,
Roy, M. A.,
Lawrence, D. A.,
Lee, J.,
Brush, J.,
Taneyhill, L. A.,
Deuel, B.,
Lew, M.,
Watanabe, C.,
Cohen, R. L.,
Melhem, M. F.,
Finley, G. G.,
Quirke, P.,
Goddard, A. D.,
Hillan, K. J.,
Gurney, A. L.,
Botstein, D.,
and Levine, A. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14717-14722[Abstract/Free Full Text]
|
| 24.
|
Tetsu, O.,
and McCormick, F.
(1999)
Nature
398,
422-426[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Shtutman, M.,
Zhurinsky, J.,
Simcha, I.,
Albanese, C.,
D'Amico, M.,
Pestell, R.,
and Ben-Ze'ev, A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
5522-5527[Abstract/Free Full Text]
|
| 26.
|
Mann, B.,
Gelos, M.,
Siedow, A.,
Hanski, M. L.,
Gratchev, A.,
Ilyas, M.,
Bodmer, W. F.,
Moyer, M. P.,
Riecken, E. O.,
Buhr, H. J.,
and Hanski, C.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1603-1608[Abstract/Free Full Text]
|
| 27.
|
Crawford, H. C.,
Fingleton, B. M.,
Rudolph-Owen, L. A.,
Goss, K. J.,
Rubinfeld, B.,
Polakis, P.,
and Matrisian, L. M.
(1999)
Oncogene
18,
2883-2891[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Koh, T. J.,
Bulitta, C. J.,
Fleming, J. V.,
Dockray, G. J.,
Varro, A.,
and Wang, T. C.
(2000)
J. Clin. Invest.
106,
533-539[Medline]
[Order article via Infotrieve]
|
| 29.
|
Rockman, S. P.,
Currie, S. A.,
Ciavarella, M.,
Vincan, E.,
Dow, C.,
Thomas, R. J.,
and Phillips, W. A.
(2001)
J. Biol. Chem.
276,
45113-45119[Abstract/Free Full Text]
|
| 30.
|
Zhang, X.,
Gaspard, J. P.,
and Chung, D. C.
(2001)
Cancer Res.
61,
6050-6054[Abstract/Free Full Text]
|
| 31.
|
Kolligs, F. T.,
Nieman, M. T.,
Winer, I., Hu, G.,
Van Mater, D.,
Feng, Y.,
Smith, I. M., Wu, R.,
Zhai, Y.,
Cho, K. R.,
and Fearon, E. R.
(2002)
Cancer Cells
1,
145-155
|
| 32.
|
Wong, N. A.,
and Pignatelli, M.
(2002)
Am. J. Pathol.
160,
389-401[Abstract/Free Full Text]
|
| 33.
|
Zennou, V.,
Petit, C.,
Guetard, D.,
Nerhbass, U.,
Montagnier, L.,
and Charneau, P.
(2000)
Cell
101,
173-185[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Wei, Y.,
Fabre, M.,
Branchereau, S.,
Gauthier, F.,
Perilongo, G.,
and Buendia, M. A.
(2000)
Oncogene
19,
498-504[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Gugen-Guillouzo, C.,
Campion, J. P.,
Brissot, P.,
Glaise, D.,
Launois, B.,
Bourel, M.,
and Guillouzo, A.
(1982)
Cell Biol. Intern. Rep.
6,
625-628[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Sirven, A.,
Ravet, E.,
Charneau, P.,
Zennou, V.,
Coulombel, L.,
Guéraed, D.,
Pflumio, F.,
and Dubart-Kupperschmitt, A.
(2001)
Mol. Ther.
3,
438-447[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Renard, C. A.,
Fourel, G.,
Bralet, M. P.,
Degott, C., De,
la Coste, A.,
Perret, C.,
Tiollais, P.,
and Buendia, M. A.
(2000)
Oncogene
19,
2678-2686[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Liao, C.,
Zhao, M.,
Song, H.,
Uchida, K.,
Yokoyama, K. K.,
and Li, T.
(2000)
Hepatology
32,
721-727[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Marty, C.,
Misset, B.,
Tamion, F.,
Fitting, C.,
Carlet, J.,
and Cavaillon, J. M.
(1994)
Crit. Care Med.
22,
673-679[Medline]
[Order article via Infotrieve]
|
| 40.
|
Tordjman, R.,
Delaire, S.,
Plouet, J.,
Ting, S.,
Gaulard, P.,
Fichelson, S.,
Romeo, P. H.,
and Lemarchandel, V.
(2001)
Blood
97,
1968-1974[Abstract/Free Full Text]
|
| 41.
|
Koch, A. E.,
Polverini, P. J.,
Kunkel, S. L.,
Harlow, L. A.,
DiPietro, L. A.,
Elner, V. M.,
Elner, S. G.,
and Strieter, R. M.
(1992)
Science
258,
1798-1801[Abstract/Free Full Text]
|
| 42.
|
Murdoch, C.,
Monk, P. N.,
and Finn, A.
(1999)
Cytokine
11,
704-712[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Inoue, K.,
Slaton, J. W.,
Kim, S. J.,
Perrotte, P.,
Eve, B. Y.,
Bar-Eli, M.,
Radinsky, R.,
and Dinney, C. P.
(2000)
Cancer Res.
60,
2290-2299[Abstract/Free Full Text]
|
| 44.
|
Kitadai, Y.,
Haruma, K.,
Sumii, K.,
Yamamoto, S., Ue, T.,
Yokozaki, H.,
Yasui, W.,
Ohmoto, Y.,
Kajiyama, G.,
Fidler, I. J.,
and Tahara, E.
(1998)
Am. J. Pathol.
152,
93-100[Abstract]
|
| 45.
|
Luca, M.,
Huang, S.,
Gershenwald, J. E.,
Singh, R. K.,
Reich, R.,
and Bar-Eli, M.
(1997)
Am. J. Pathol.
151,
1105-1113[Abstract]
|
| 46.
|
Schadendorf, D.,
Moller, A.,
Algermissen, B.,
Worm, M.,
Sticherling, M.,
and Czarnetzki, B. M.
(1993)
J. Immunol.
151,
2667-2675[Abstract]
|
| 47.
|
Akiba, J.,
Yano, H.,
Ogasawara, S.,
Higaki, K.,
and Kojiro, M.
(2001)
Int. J. Oncol.
18,
257-264[Medline]
[Order article via Infotrieve]
|
| 48.
|
Shimoda, K.,
Begum, N. A.,
Shibuta, K.,
Mori, M.,
Bonkovsky, H. L.,
Banner, B. F.,
and Barnard, G. F.
(1998)
Hepatology
28,
108-115[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Dong, G.,
Chen, Z., Li, Z. Y.,
Yeh, N. T.,
Bancroft, C. C.,
and Van Waes, C.
(2001)
Cancer Res.
61,
5911-5918[Abstract/Free Full Text]
|
| 50.
|
Satyamoorthy, K., Li, G.,
Vaidya, B.,
Kalabis, J.,
and Herlyn, M.
(2002)
Cell Growth Differ.
13,
87-93[Abstract/Free Full Text]
|
| 51.
|
Playford, M. P.,
Bicknell, D.,
Bodmer, W. F.,
and Macaulay, V. M.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
12103-12108[Abstract/Free Full Text]
|
| 52.
|
Monga, S. P.,
Mars, W. M.,
Pediaditakis, P.,
Bell, A.,
Mule, K.,
Bowen, W. C.,
Wang, X.,
Zarnegar, R.,
and Michalopoulos, G. K.
(2002)
Cancer Res.
62,
2064-2071[Abstract/Free Full Text]
|
| 53.
|
Xie, P.
(2001)
Cytokines Growth Factors Rev.
12,
375-391
|
| 54.
|
Yoong, K. F.,
Afford, S. C.,
Jones, R.,
Aujla, P.,
Qin, S.,
Price, K.,
Hubscher, S. G.,
and Adams, D. H.
(1999)
Hepatology
30,
100-111[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Hlubek, F.,
Jung, A.,
Kotzor, N.,
Kirchner, T.,
and Brabletz, T.
(2001)
Cancer Res.
61,
8089-8093[Abstract/Free Full Text]
|
| 56.
|
Ougolkov, A. V.,
Yamashita, K.,
Mai, M.,
and Minamoto, T.
(2002)
Gastroenterology
122,
60-71[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore 